Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has adjusted its course after announcing mixed clinical trial results for its melanoma drug, according to Sound Shore Management's Q2 2026 investor letter. The biopharmaceutical company, which closed at $814.79 per share on August 26, 2026, with a market capitalization of $83.89 billion, saw its shares gain 40.58% over the past 52 weeks but returned a portion of earlier advances following the trial news. Sound Shore initiated its position when the stock traded at 13 times earnings with an 8% free cash flow yield, citing a fortress balance sheet and promising pipeline drugs. The fund's Investor Class and Institutional Class rose 10.48% and 10.58% in the second quarter, trailing the Russell 1000 Value Index's 13.87% and the S&P 500's 15.20% returns.
Regeneron Pharmaceuticals IncMixed melanoma drug trial results led to a pullback in shares.
